Low Libido (Women)
Peptides for low libido in women — PT-141 (Vyleesi, FDA-approved for HSDD), oxytocin — with mechanism, evidence from pivotal trials, and how peptide therapy fits the female sexual wellness landscape.
Low libido in women — formally hypoactive sexual desire disorder (HSDD) or female sexual interest/arousal disorder (FSIAD) — is the persistent or recurrent absence or reduction of sexual desire causing personal distress, not better explained by a medical condition, medication, or relationship factors. The condition affects an estimated 8-10% of premenopausal women and a higher proportion of postmenopausal women, with significant impact on quality of life and intimate relationships. The diagnosis requires both reduced desire AND personal distress — many women have lower desire without distress and do not need treatment.
The female sexual response involves multiple interacting systems: hormonal (estrogen, testosterone), neurotransmitter (dopamine, serotonin, melanocortin signaling), vascular (clitoral and genital blood flow), and psychosocial (relationship factors, stress, history). Treatment is increasingly recognized as multimodal: psychotherapy and couples therapy where appropriate, treatment of contributing conditions (depression, anxiety, hormonal imbalance, vaginal atrophy in postmenopausal women), and pharmacological interventions when warranted.
The pharmacological landscape has expanded meaningfully. Flibanserin (Addyi) was FDA-approved in 2015 as the first drug for HSDD, working through serotonin receptor modulation. Bremelanotide (Vyleesi/PT-141) was FDA-approved in 2019 — a peptide injection for as-needed use that activates melanocortin-4 receptors in the central nervous system. Estrogen and testosterone therapy in appropriate patients addresses the hormonal contributions. Bupropion has off-label use for SSRI-induced sexual dysfunction.
Peptide therapy for low libido in women has the unique status of including PT-141 — an FDA-approved peptide specifically for this indication. This makes it different from most peptides in the catalog: not investigational, not off-label adjunct, but a validated and approved intervention. Oxytocin has a smaller role in some compounded formulations targeting bonding and intimacy. This page covers what's actually known, where the evidence is strongest, and how peptide therapy fits female sexual wellness care. It is informational, not medical advice.
Peptides discussed for Low Libido (Women)
Oxytocin
Neuropeptide Hormone
A naturally occurring neuropeptide involved in social bonding, trust, and reproduction, FDA-approved for labor induction.
PT-141 (Bremelanotide)
Melanocortin Receptor Agonist
An FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder in premenopausal women, also studied for broader sexual dysfunction.
How peptides target low libido (women)
PT-141 (bremelanotide, marketed as Vyleesi) is FDA-approved for HSDD in premenopausal women based on the RECONNECT Phase 3 program. The mechanism is unique among sexual wellness drugs: PT-141 activates melanocortin-4 receptors (MC4R) in the central nervous system, triggering downstream dopaminergic and oxytocinergic signaling that promotes sexual desire and arousal. The on-demand subcutaneous injection (administered 45 minutes before anticipated sexual activity) makes it different from chronic-use medications.
Oxytocin (the 'bonding hormone') has been explored in compounded formulations for intimacy and emotional bonding. Some practitioners use it in nasal spray or sublingual form, often combined with PT-141 or other interventions. Oxytocin's mechanism — activation of central oxytocin receptors involved in social cognition, trust, and bonding — provides theoretical relevance for the relational component of sexual wellness. Evidence for oxytocin specifically as a sexual wellness intervention is more limited than for PT-141.
The FDA-approved status of PT-141 for HSDD is the central differentiator. Unlike most peptides discussed on this site, PT-141 has Phase 3 RCT validation, FDA approval, and an established place in the sexual wellness treatment hierarchy.
What the evidence shows
PT-141 has the strongest peptide evidence for any indication in this site's catalog. The RECONNECT Phase 3 program (two trials, RECONNECT and RECONNECT-2) demonstrated statistically significant improvements in sexual desire (measured by FSFI-D scores) and reductions in distress (FSDS-DAO) in premenopausal women with HSDD versus placebo. Safety analyses across the development program show a manageable side effect profile with nausea as the most common adverse event. FDA approval in 2019 followed.
For the broader treatment landscape: flibanserin (Addyi) has Phase 3 evidence with FDA approval, providing a chronic-use oral alternative. Estrogen therapy in postmenopausal women with vaginal atrophy and hormone-related desire reduction has substantial evidence. Testosterone therapy in selected postmenopausal women has evidence for desire improvement (off-label in the US; approved in some other jurisdictions). Bupropion has off-label evidence for SSRI-induced sexual dysfunction.
Oxytocin has small studies suggesting some role in female sexual function, but evidence is much more limited than PT-141.
Peptide therapy is now part of evidence-validated sexual wellness care for women through PT-141. Compounded oxytocin formulations are adjunctive and less well-validated.
What to expect
PT-141 is dosed as a 1.75 mg subcutaneous injection 45 minutes before anticipated sexual activity, with maximum 1 dose per 24 hours and 8 doses per month. Effects typically include increased subjective desire and arousal during the relevant window. Approximately 25% of women in trials had a clinically meaningful response (defined by improvement on FSFI-D and FSDS-DAO).
Nausea is the most common side effect, affecting approximately 40% of patients, typically mild-to-moderate and improving with subsequent doses. Other side effects include flushing, headache, and injection-site reactions. Transient blood pressure elevation is documented but typically modest.
What to NOT expect: response in every patient, dramatic improvement comparable to addressing relationship factors or fundamental hormonal causes when those are the predominant issues, or complete restoration of desire to a previous baseline. PT-141 modulates the sexual response system; it does not address relationship issues, depression, hormonal causes, or psychosocial factors that may be the primary drivers in some patients.
Important caveats
Female sexual wellness evaluation should be coordinated by a clinician familiar with FSIAD/HSDD — gynecologist with sexual medicine focus, primary care clinician with sexual medicine interest, or sexual medicine specialist. The diagnosis itself requires distress associated with the desire reduction; women without distress do not have HSDD and do not need treatment.
Contributing factors should be evaluated: depression (treat the depression), anxiety, relationship issues (couples therapy), medications causing sexual dysfunction (SSRI-induced sexual dysfunction is common; bupropion may help), hormonal factors (estrogen for vaginal atrophy; testosterone for selected postmenopausal patients), and chronic medical conditions affecting libido.
PT-141 is approved only for premenopausal women with acquired generalized HSDD. Postmenopausal women, women with sexual dysfunction primarily from other causes, and women whose sexual difficulty is better explained by other diagnoses are not in the FDA-approved population.
Blood pressure considerations: PT-141 produces transient blood pressure increases. Patients with uncontrolled hypertension or known cardiovascular disease should be evaluated before use. The labeling includes monitoring guidance.
Compounded peptide formulations (combining PT-141 with oxytocin, sometimes with L-theanine or other ingredients) are marketed in some clinics. The FDA-approved Vyleesi product is PT-141 alone; compounded combinations are off-label.
Frequently asked questions
Is there a peptide approved for low libido in women?
Yes. Bremelanotide (PT-141, marketed as Vyleesi) is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is administered as a subcutaneous injection 45 minutes before anticipated sexual activity. Approval is based on the RECONNECT Phase 3 program demonstrating significant improvements in desire and reductions in distress.
How does PT-141 work for low libido?
PT-141 activates melanocortin-4 receptors (MC4R) in the central nervous system, triggering downstream dopaminergic and oxytocinergic pathways involved in sexual desire and arousal. The mechanism is distinct from PDE5 inhibitors (sildenafil, tadalafil) which are vascular drugs and do not address central desire. PT-141 acts centrally on the desire pathways themselves.
Does PT-141 work for postmenopausal women?
FDA approval is specifically for premenopausal women. Postmenopausal women may use it off-label, but the evidence base in this population is more limited and other interventions (estrogen for vaginal atrophy, testosterone for selected patients) are often the primary considerations. Discuss with a gynecologist or sexual medicine specialist familiar with postmenopausal sexual wellness.
What about oxytocin for female intimacy?
Oxytocin has been explored in compounded sexual wellness formulations, often combined with PT-141. The mechanism (central oxytocin receptor activation involved in bonding, trust, social cognition) provides theoretical relevance for the relational component of sexual wellness. Evidence is more limited than for PT-141. Some clinics offer combination PT-141 + oxytocin nasal spray formulations as 'intimacy stack' products; these are off-label compounded preparations.
Will PT-141 help if my low libido is from antidepressants?
Possibly, but addressing the underlying medication is often the priority. SSRI-induced sexual dysfunction (decreased libido, anorgasmia) is common; switching to bupropion (which has lower sexual side effects) or adding bupropion is often effective. Vyleesi may help in patients who need to remain on SSRI therapy. The right framing: identify and address the SSRI contribution first; consider PT-141 as an adjunct if needed.
Part of these goals
Related conditions
Peptide families relevant to Low Libido (Women)
Stacks that overlap
- PT-141 + Oxytocin (The Intimacy Stack)
Combines PT-141's central arousal signaling with oxytocin's bonding and emotional connection effects for a comprehensive approach to sexual wellness and intimacy.
Updated 2026-05-08